Cargando…
NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion
Nicotinamide phosphoribosyl transferase (NAMPT) is considered as a promising target for cancer therapy given its critical engagement in cancer metabolism and inflammation. However, therapeutic benefit of NAMPT enzymatic inhibitors appears very limited, likely due to the failure to intervene non-enzy...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214341/ https://www.ncbi.nlm.nih.gov/pubmed/35755293 http://dx.doi.org/10.1016/j.apsb.2021.12.017 |
_version_ | 1784730993991614464 |
---|---|
author | Wu, Ying Pu, Congying Fu, Yixian Dong, Guoqiang Huang, Min Sheng, Chunquan |
author_facet | Wu, Ying Pu, Congying Fu, Yixian Dong, Guoqiang Huang, Min Sheng, Chunquan |
author_sort | Wu, Ying |
collection | PubMed |
description | Nicotinamide phosphoribosyl transferase (NAMPT) is considered as a promising target for cancer therapy given its critical engagement in cancer metabolism and inflammation. However, therapeutic benefit of NAMPT enzymatic inhibitors appears very limited, likely due to the failure to intervene non-enzymatic functions of NAMPT. Herein, we show that NAMPT dampens antitumor immunity by promoting the expansion of tumor infiltrating myeloid derived suppressive cells (MDSCs) via a mechanism independent of its enzymatic activity. Using proteolysis-targeting chimera (PROTAC) technology, PROTAC A7 is identified as a potent and selective degrader of NAMPT, which degrades intracellular NAMPT (iNAMPT) via the ubiquitin–proteasome system, and in turn decreases the secretion of extracellular NAMPT (eNAMPT), the major player of the non-enzymatic activity of NAMPT. In vivo, PROTAC A7 efficiently degrades NAMPT, inhibits tumor infiltrating MDSCs, and boosts antitumor efficacy. Of note, the anticancer activity of PROTAC A7 is superior to NAMPT enzymatic inhibitors that fail to achieve the same impact on MDSCs. Together, our findings uncover the new role of enzymatically-independent function of NAMPT in remodeling the immunosuppressive tumor microenvironment, and reports the first NAMPT PROTAC A7 that is able to block the pro-tumor function of both iNAMPT and eNAMPT, pointing out a new direction for the development of NAMPT-targeted therapies. |
format | Online Article Text |
id | pubmed-9214341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92143412022-06-23 NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion Wu, Ying Pu, Congying Fu, Yixian Dong, Guoqiang Huang, Min Sheng, Chunquan Acta Pharm Sin B Original Article Nicotinamide phosphoribosyl transferase (NAMPT) is considered as a promising target for cancer therapy given its critical engagement in cancer metabolism and inflammation. However, therapeutic benefit of NAMPT enzymatic inhibitors appears very limited, likely due to the failure to intervene non-enzymatic functions of NAMPT. Herein, we show that NAMPT dampens antitumor immunity by promoting the expansion of tumor infiltrating myeloid derived suppressive cells (MDSCs) via a mechanism independent of its enzymatic activity. Using proteolysis-targeting chimera (PROTAC) technology, PROTAC A7 is identified as a potent and selective degrader of NAMPT, which degrades intracellular NAMPT (iNAMPT) via the ubiquitin–proteasome system, and in turn decreases the secretion of extracellular NAMPT (eNAMPT), the major player of the non-enzymatic activity of NAMPT. In vivo, PROTAC A7 efficiently degrades NAMPT, inhibits tumor infiltrating MDSCs, and boosts antitumor efficacy. Of note, the anticancer activity of PROTAC A7 is superior to NAMPT enzymatic inhibitors that fail to achieve the same impact on MDSCs. Together, our findings uncover the new role of enzymatically-independent function of NAMPT in remodeling the immunosuppressive tumor microenvironment, and reports the first NAMPT PROTAC A7 that is able to block the pro-tumor function of both iNAMPT and eNAMPT, pointing out a new direction for the development of NAMPT-targeted therapies. Elsevier 2022-06 2021-12-31 /pmc/articles/PMC9214341/ /pubmed/35755293 http://dx.doi.org/10.1016/j.apsb.2021.12.017 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Wu, Ying Pu, Congying Fu, Yixian Dong, Guoqiang Huang, Min Sheng, Chunquan NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title_full | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title_fullStr | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title_full_unstemmed | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title_short | NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
title_sort | nampt-targeting protac promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214341/ https://www.ncbi.nlm.nih.gov/pubmed/35755293 http://dx.doi.org/10.1016/j.apsb.2021.12.017 |
work_keys_str_mv | AT wuying nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion AT pucongying nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion AT fuyixian nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion AT dongguoqiang nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion AT huangmin nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion AT shengchunquan nampttargetingprotacpromotesantitumorimmunityviasuppressingmyeloidderivedsuppressorcellexpansion |